MWNA
CRNX icon

Marshall Wace North America’s Crinetics Pharmaceuticals CRNX Stock Holding History

Marshall Wace North America’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-43,671
Closed -$824K – 1474
2021
Q2 		$824K Buy
+43,671
New +$767K ﹤0.01% 1068
2019
Q4 		– Sell
-2,965
Closed -$45K – 1332
2019
Q3 		$45K Sell
2,965
-70,960
-96% -$1.38M ﹤0.01% 1168
2019
Q2 		$1.85M Buy
73,925
+72,014
+3,768% +$1.78M 0.01% 586
2019
Q1 		$43K Buy
+1,911
New +$47K ﹤0.01% 1291
2018
Q4 		– Sell
-31,241
Closed -$895K – 1501
2018
Q3 		$895K Buy
+31,241
New +$928K 0.01% 620

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return